Pharmacological management of allergic rhinitis: A consensus statement from the Malaysian Society of Allergy and Immunology

• Main Authors: Abdullah, Baharudin, Latiff, Amir Hamzah Abdul, Manuel, Anura Michelle, Jamli, Faizah Mohamed, Singh, Harvinder Singh Dalip, Ismail, Intan Hakimah, Jahendran, Jeevanan, Saniasiaya, Jeyasakthy, Woo, Kent Chee Keen, Khoo, Phaik Choo, Singh, Kuljit, Mohammad, Nurashikin, Mohamad, Sakinah, Husain, Salina, Moesges, Ralph
• Format: Article
• Published: Dove Medical Press Ltd. 2022
• Subjects: RF Otorhinolaryngology; RM Therapeutics. Pharmacology
• Online Access: http://eprints.um.edu.my/41778/
• Institution: Universiti Malaya

The goal of allergic rhinitis (AR) management is to achieve satisfactory symptom control to ensure good quality of life. Most patients with AR are currently treated with pharmacotherapy. However, knowledge gaps on the use of pharmacotherapy still exist among physicians, particularly in the primary care setting, despite the availability of guideline recommendations. Furthermore, it is common for physicians in the secondary care setting to express uncertainty regarding the use of new combination therapies like intranasal corticosteroid plus antihistamine combinations. Inadequate treatment leads to significant reduction of quality of life that affects daily activities at home, work, and school. With these concerns in mind, a practical consensus statement was developed to complement existing guidelines on the rational use of pharmacotherapy in both the primary and secondary care settings.